Ways To Face New Bio Funding & Banking Risks

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Funding bio startups has never been easy, but there’s no doubt that it just got harder. We wanted to find at least one company to talk about how it is handling the damage and aftermath of recent bank closures and other cash crunches, and we actually found two. Lisa Ricciardi, CEO of Cognition Therapeutics, and Allan Shaw, CFO of Portage Biotech, here share their views, knowledge, and advice on ways to manage this new funding challenge.